Prevalence and clinical significance of RBM3 immunostaining in non-small cell lung cancers

ConclusionsIn summary, our study shows that loss of RBM3 expression predicts worse clinical outcome in LUAC patients.

Source: Journal of Cancer Research and Clinical Oncology - February 13, 2019 Category: Cancer & Oncology Source Type: research